Feature | January 23, 2014

Nanotherapy Advancement May Help Reduce Recurrent Heart Attacks and Stroke

HDL nanoparticle delivers statin medication to inflamed blood vessels, prevents repeat heart attacks, stroke

January 23, 2014 — Up to 30 percent of heart attack patients suffer an additional heart attack because of limited ability to control inflammation inside heart arteries that leads to clots rupturing and myocardial infarction or stroke.
 
An international research team, led by Icahn School of Medicine at Mount Sinai investigators, designed and tested a high-density lipoprotein (HDL) nanoparticle loaded with a statin drug. In mouse studies, they show HDL nanotherapy is capable of directly targeting and lowering dangerous inflammation in blood vessels.
 
HDL nanotherapy could potentially avert repeat heart attacks and may also reduce recurrent strokes caused by clots in brain arteries. 
 
The nanoparticles resemble HDL cholesterol particles and bind to the same receptors as natural HDL in order to deliver the statin drug. Oral statin medications work primarily in the liver to reduce levels of unhealthy lipids circulating in the blood. Statins also exert a very weak dampening effect on some inflammatory cells, foremost macrophages that hide in plaque in arterial walls. Researchers sought to bolster this anti-inflammatory function in their HDL nanotherapy design.
 
 “Levels of inflammation spike after a heart attack, which is why up to 30 percent of heart attack patients may suffer another heart attack, some while in hospital or just after discharge,” said co-author Zahi Fayad, Ph.D., professor of radiology and director of the Translational and Molecular Imaging Institute at Icahn.
 
According to Mount Sinai researchers, the best way to use their HDL nanotherapy is by injection after the clot that produces a heart attack or stroke has been treated. The HDL nanoparticle would deliver the statin directly to macrophages that are driving the inflammatory response.
“Our study also confirms that the HDL nanoparticle is not seen as a foreign invader by the body’s immune system and that it has an inherent and natural affinity to target plaque macrophages,” said first author Jun Tang, Ph.D, M.S.
 
The team intends to conduct a clinical trial to test the HDL nanotherapy on humans. 
 
For more information: www.mountsinai.org

Related Content

News | Cardiac Diagnostics| June 24, 2016
Measuring antibody levels in the blood could be used to detect a person’s heart attack risk after researchers, part-...
Zoll LifeVest wearable defibrillator, WEARIT-II Registry results, CardioStim EuroPace 2016
News | Defibrillator Monitors| June 21, 2016
Zoll Medical Corp. announced that patients experience a high one-year survival rate following use of the LifeVest...
Sponsored Content | Videos | Structural Heart Occluders| June 16, 2016
This is an animation of how a Gore Cardioform Septal Occluder is implanted for the transcatheter closure of ASDs or P
News | Implantable Cardioverter Defibrillators (ICD)| June 14, 2016
Medtronic plc announced results from several feasibility studies evaluating a new approach to implantable cardioverter...
hypertrophic cardiomyopathy, HCM, strain echocardiography, risk assessment, ASE 2016
News | Cardiovascular Ultrasound| June 13, 2016
After following a large sub-set of patients, researchers found that by using strain echocardiography they could...
ASE 2016, Mayo Clinic study, echocardiography, aortic flow rate, patient risk stratification
News | Cardiovascular Ultrasound| June 13, 2016
Researchers from Mayo Clinic believe they have found a better way to risk stratify some of their most fragile patients.
GE Healthcare, Getinge Group, Maquet, Discovery IGS 730 angiography system, Magnus operating table, integrated, hybrid OR

GE Healthcare's Discovery IGS 730 angiography system

Technology | Hybrid OR| June 13, 2016
GE Healthcare and Getinge Group announced the U.S. launch of a new, highly flexible angiography solution for surgery,...
Inventory management, cath lab inventory management, automated inventory management
Sponsored Content | Webinar | Inventory Management| June 10, 2016
Do you find products are stocked based on intuition rather than actual utilization based on clinical demand?
hemmorhagic stroke, blood pressure management, ATACH II trial, NINDS

Brain scan showing damage caused by bleeding during a hemorrhagic stroke. Image courtesy of Adnan I Qureshi, M.D., University of Minnesota.

News | Stroke| June 09, 2016
June 9, 2016 — An international stroke study
Medtronic, Micra TPS pacemaker, Global Clinical Trial, Cardiostim 2016
News | Pacemakers| June 09, 2016
Medtronic plc announced new results from the Medtronic Micra Transcatheter Pacing System (TPS) Global Clinical Trial in...
Overlay Init